Navigation Links
Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
Date:1/24/2012

; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions; market acceptance of and continued demand for Watson's products; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Watson's facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on form 10-K for the year ended December 31, 2010 and its Quarterly Report on Form 10-Q for the period ended September 30, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

The following table presents a reconciliation of forecasted net income for the twelve months ended December 31, 2011 to adjusted non-GAAP net income and adjusted earnings per diluted share:Reconciliation Table(Unaudited; in millions except per share amounts)Twelve Months EndedDecember 31,20112011 Low High GAAP to non-GAAP net income calculationReported GAAP net income attributable to
 common shareholders $
258.0 $
261.0 Adjusted for:Amortization355.5 355.5 Global supply chain initiative(1).0 .0 Acquisition and licensing charges30.0 30.0 Interest accretion on contingent liabilities38.0 38.0 Non-cash impairment/asset sales42.0 44.0 Non-recurring (gains) losses(13.0)(13.0)Legal settlements5.0 5.0 Income taxes on items above(131.0)(133.0)Non-GAAP net incom
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Watson Acquires Ascent Pharmahealth for AU$375 Million
2. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
4. Watson Launches Generic LoSEASONIQUE(R)
5. Watson Launches Generic LIPITOR®
6. Watson to Present at the 2011 Piper Jaffray Health Care Conference
7. Watson Wins Kentucky Drug Pricing Litigation
8. Watson Confirms Exelon(R) Patent Challenge
9. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
10. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
11. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
(Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Share the hope." With these words, Lilly USA, LLC, ... the 2010 Oncology On Canvas: Expressions of a Cancer ... biennial competition invites residents of the United States and Puerto ... members, friends, caregivers and healthcare providers - to express, through ...
... Inc. (Nasdaq: OREX ), a biopharmaceutical company focused ... results for the three months ended September 30, 2009. ... , As of September 30, 2009, Orexigen held ... additional $50.9 million in investment securities, available-for-sale. Together, ...
Cached Medicine Technology:Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 2Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 3Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 4Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 5Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports ... , Instead of risking containment — or even destruction — of products, an ...
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... patients using the RenovoCath,™ a novel catheter that was developed for targeted delivery ... pancreatic cancer are now being treated at Florida Hospital Tampa with the device ...
(Date:7/31/2015)... ... ... Ticket Down is a reputable source of authentic USA vs. Australia tickets ... the Australia Women's National Team in two separate friendly contests. The first match ... second match will occur in Birmingham, Alabama at Legion Field. These friendly international ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... has found that major surgeries and operations could prove deadly ... showed that elderly men with even slightly irregular red blood ... major surgery. ,The study, which examined data from ... to demonstrate that even minor anaemia or polycythemia, when the ...
... the wrappers of the diabetes drug Avandia will soon start ... congestive heart failure . ,Some of the experts, ... that the delay in implementation is an example of industry ... ,GlaxoSmithKline's Avandia has been in use since 1999. The ...
... number of panthers is slowly on the rise . ... estimates of the census figures indicated an increase in the ... to the 2004 wildlife census, there were over 550 panthers ... Park, has the maximum number at 83. At least 15 ...
... Bean will soon be available in the South Asian markets, ... licensing agent for India, Pakistan, Bangladesh and Nepal has inked ... popular character portrayed by Rowan Atkinson to the South Asia ... the television producer of the popular comedy series Mr. Bean. ...
... keep children as safe as possible in cars, leaving parents ... major review of restraint legislation, accident statistics and parent surveys ... graduate to an adult seatbelt without the use of ... or about 11 years old, and that children under 12 ...
... Taking serious note of doctors using advertisements to lure ... Monday asked the state's medical council to take steps ... education and research minister Tikshan Sood said here that ... but also a violation of the Medical Council Act. ...
Cached Medicine News:Health News:Major Surgeries and Operations Could Prove Deadly for Anaemic Older Men 2Health News:Child Car Seat Danger 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: